Resveratrol glucuronides as the metabolites of resveratrol in humans: Characterization, synthesis, and anti-HIV activity

Journal of Pharmaceutical Sciences

Volumn 93, Issue 10, 2004, Pages 2448-2457

  Wang, Lai Xi ^a   Heredia, Alonso ^a   Song, Haijing ^a   Zhang, Zhaojun ^b   Yu, Biao ^b   Davis, Charles ^a   Redfield, Robert ^a  

^a INSTITUTE OF HUMAN VIROLOGY   (United States)

^b SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY   (China)

Author keywords

Anti HIV activity; Glucuronide; Glycosylation; Metabolite; Resveratrol

Indexed keywords

BETA GLUCURONIDASE; DIDANOSINE; DRUG METABOLITE; RESVERATROL; RESVERATROL 3' O GLUCURONIDE; RESVERATROL 4' O GLUCURONIDE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CELL VIABILITY; CLINICAL TRIAL; CYTOTOXICITY; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG POTENTIATION; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; GLUCURONIDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PROTON NUCLEAR MAGNETIC RESONANCE; SIDE EFFECT;

EID: 4844223990     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20156     Document Type: Article

References (49)

1. Pervaiz S. 2003. Resveratrol: From grapevines to mammalian biology. FASEB J 17(14):1975-1985.
2. Wang Y, Catana F, Yang Y, Roderick R, van Breemen RB. 2002. An LC-MS method for analyzing total resveratrol in grape juice, cranberry juice, and in wine. J Agric Food Chem 50(3):431-435.
3. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275(5297):218-220.
4. Jang M, Pezzuto JM. 1999. Cancer chemopreventive activity of resveratrol. Drugs Exp Clin Res 25(2-3):65-77.
5. Frankel EN, Waterhouse AL, Kinsella JE. 1993. Inhibition of human LDL oxidation by resveratrol. Lancet 341(8852):1103-1104.
6. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, Goldberg DM. 1995. The red wine phenolics transresveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: Implications for protection against coronary heart disease. Clin Chim Acta 235(2):207-219.
7. Schouten A, Wagemakers L, Stefanato FL, van der Kaaij RM, van Kan JA. 2002. Resveratrol acts as a natural profungicide and induces self-intoxication by a specific laccase. Mol Microbiol 43(4):883-894.
8. Gehm BD, McAndrews JM, Chien PY, Jameson JL. 1997. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA 94(25):14138-14143.
9. Kopp P. 1998. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conund-rum of the 'French paradox'? Eur J Endocrinol 138(6):619-620.
10. Lu R, Serrero G. 1999. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol 179(3):297-304.
11. Das DK, Sato M, Ray PS, Maulik G, Engelman RM, Bertelli AA, Bertelli A. 1999. Cardioprotection of red wine: Role of polyphenolic antioxidants. Drugs Exp Clin Res 25(2-3):115-120.
12. Pace-Asciak CE, Rounova O, Hahn SE, Diamandis EP, Goldberg DM. 1996. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin Chim Acta 246(1-2):163-182.
13. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA. 2003. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425:191-196.
14. Fuhrman B, Lavy A, Aviram M. 1995. Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation. Am J Clin Nutr 61(3):549-554.
15. Belguendouz L, Fremont L, Linard A. 1997. Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins. Biochem Pharmacol 53(9):1347-1355.
16. Stojanovic S, Sprinz H, Brede O. 2001. Efficiency and mechanism of the antioxidant action of trans-resveratrol and its analogues in the radical liposome oxidation. Arch Biochem Biophys 391(1):79-89.
17. Jang M, Pezzuto JM. 1998. Effects of resveratrol on 12-O- tetradecanoylphorbol-13-acetate-induced oxidative events and gene expression in mouse skin. Cancer Lett 134(1):81-89.
18. Miloso M, Bertelli AA, Nicolini G, Tredici G. 1999. Resveratrol-induced activation of the mitogen-activated protein kinases, ERK1 and ERK2, in human neuroblastoma SH-SY5Y cells. Neurosci Lett 264(1-3):141-144.
19. Fulgenzi A, Bertelli AA, Magni E, Ferrero E, Ferrero ME. 2001. In vivo inhibition of TNFalpha-induced vascular permeability by resveratrol. Transplant Proc 33(3):2341-2343.
20. Ferrero ME, Bertelli AE, Fulgenzi A, Pellegatta F, Corsi MM, Bonfrate M, Ferrara F, De Caterina R, Giovannini L, Bertelli A. 1998. Activity in vitro of resveratrol on granulocyte and monocyte adhesion to endothelium. Am J Clin Nutr 68(6):1208-1214.
21. Stivala LA, Savio M, Carafoli F, Perucca P, Bianchi L, Maga G, Forti L, Pagnoni UM, Albini A, Prosperi E, Vannini V. 2001. Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J Biol Chem 276(25):22586-22594.
22. Rotondo S, Rajtar G, Manarini S, Celardo A, Rotillo D, de Gaetano G, Evangelista V, Cerletti C. 1998. Effect of trans-resveratrol, a natural polyphenolic compound, on human polymorphonuclear leukocyte function. Br J Pharmacol 123(8):1691-1699.
23. Delmas D, Rebe C, Lacour S, Filomenko R, Athias A, Gambert P, Cherkaoui-Malki M, Jannin B, Dubrez-Daloz L, Latruffe N, Solary E. 2003. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J Biol Chem 278(42):41482-41490.
24. Scarlatti F, Sala G, Somenzi G, Signorelli P, Sacchi N, Ghidoni R. 2003. Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling. FASEB J 17(15):2339-2341.
25. Heredia A, Davis C, Redfield R. 2000. Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol. J Acquir Immune Defic Syndr 25(3):246-255.
26. Ragione FD, Cucciolla V, Borriello A, Pietra VD, Racioppi L, Soldati G, Manna C, Galletti P, Zappia V. 1998. Resveratrol arrests the cell division cycle at S/G2 phase transition. Biochem Biophys Res Commun 250(1):53-58.
27. Kuhnle G, Spencer JP, Chowrimootoo G, Schroeter H, Debnam ES, Srai SK, Rice-Evans C, Hahn U. 2000. Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem Biophys Res Commun 272(1):212-217.
28. Aumont V, Krisa S, Battaglia E, Netter P, Richard T, Merillon JM, Magdalou J, Sabolovic N. 2001. Regioselective and stereospecific glucuronidation of trans- and cis-resveratrol in human. Arch Biochem Biophys 393(2):281-289.
29. Yu C, Shin YG, Chow A, Li Y, Kosmeder JW, Lee YS, Hirschelman WH, Pezzuto JM, Mehta RG, van Breemen RB. 2002. Human, rat, and mouse metabolism of resveratrol. Pharm Res 19(12):1907-1914.
30. Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, Ducharme MP. 2002. Metabolism and disposition of resveratrol in rats: Extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 302(1):369-373.
31. Bollenback GN, Long JW, Benjamin DG, Lindquist JA. 1955. The synthesis of aryl-D-glucopyranosiduronic acids. J Am Chem Soc 77:3310-3315.
32. Coutant C, Jacquinet JC. 1995. 2-Deoxy-2-trichloroacetamido-D- glucopyranose derivatives in oligosaccharide synthesis: From hyaluronic acid to chondroitin 4-sulfate trisaccharides. J Chem Soc Perkin Trans 1:1573-1581.
33. Zhang Z, Yu B. 2003. Total synthesis of the antiallergic naphtho-alpha-pyrone tetraglucoside, cassiaside C(2), isolated from cassia seeds. J Org Chem 68(16):6309-6313.
34. Regev-Shoshani G, Shoseyov O, Bilkis I, Kerem Z. 2003. Glycosylation of resveratrol protects it from enzymic oxidation. Biochem J 374(Pt 1):157-163.
35. Orsini F, Pelizzoni F, Verotta L, Aburjai T, Rogers CB. 1997. Isolation, synthesis, and antiplatelet aggregation activity of resveratrol 3-O-beta-D-glucopyranoside and related compounds. J Nat Prod 60(11):1082-1087.
36. Orsini F, Pelizzoni F, Bellini B, Miglierini G. 1997. Synthesis of biologically active polyphenolic glycosides (combretastatin and resveratrol series). Carbohydr Res 301(3-4):95-109.
37. Learmonth DA. 2003. A concise synthesis of the 3-O-beta-D- and 4′-O-beta-D-glucuronide conjugates of trans-resveratrol. Bioconjug Chem 14(1):262-267.
38. Sperker B, Backman JT, Kroemer HK. 1997. The role of beta-glucuronidase in drug disposition and drug targeting in humans. Clin Pharmacokinet 33(1):18-31.
39. Sperker B, Murdter TE, Schick M, Eckhardt K, Bosslet K, Kroemer HK. 1997. Interindividual variability in expression and activity of human beta-glucuronidase in liver and kidney: Consequences for drug metabolism. J Pharmacol Exp Ther 281(2):914-920.
40. Corrales-Hernandez JJ, Gonzalez-Buitrago JM, Pastor-Encinas I, Garcia-Diez LC, Miralles JM. 1988. Androgen environment and beta-glucuronidase activity in the human kidney. Arch Androl 20(3):185-191.
41. Fishman WH, Kato K, Anstiss CL, Green S. 1967. Human serum beta-glucuronidase: Its measurement and some of its properties. Clin Chim Acta 15(3):435-447.
42. Houba PH, Boven E, Erkelens CA, Leenders RG, Scheeren JW, Pinedo HM, Haisma HJ. 1998. The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts. Br J Cancer 78(12):1600-1606.
43. Leu YL, Roffler SR, Chern JW. 1999. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT). J Med Chem 42(18):3623-3628.
44. de Graaf M, Boven E, Scheeren HW, Haisma HJ, Pinedo HM. 2002. Beta-glucuronidase-mediated drug release. Curr Pharm Des 8(15):1391-1403.
45. Schmidt F, Monneret C. 2003. Prodrug mono therapy: Synthesis and biological evaluation of an etoposide glucuronide-prodrug. Bioorg Med Chem 11(10):2277-2283.
46. Prijovich ZM, Leu YL, Roffler SR. 2003. Stability of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in the presence of human serum albumin. Biochem Pharmacol 66(7):1181-1187.
47. Boyer MJ, Tannock IF. 1993. Lysosomes, lysosomal enzymes, and cancer. Adv Cancer Res 60:269-291.
48. Ohta H, Ono M, Sekiya C, Namiki M. 1992. Serum immunoreactive beta-glucuronidase determined by an enzyme-linked immunosorbent assay in patients with hepatic diseases. Clin Chim Acta 208(1-2):9-21.
49. Saha AK, Glew RH, Kotler DP, Omene JA. 1991. Elevated serum beta-glucuronidase activity in acquired immunodeficiency syndrome. Clin Chim Acta 199(3):311-316.